An autologous CAR-T cell therapy for treating relapsed or refractory B-cell Non-Hodgkin’s Lymphoma and B-cell Acute Lymphoblastic Leukemia by genetically modifying patient T-cells to target and destroy cancerous B-cells.

A technology platform enabling in-house production of CAR-T cell therapies, including lentiviral vector and plasmid manufacturing, to control the entire CAR-T cell production process.